Methods for treatment of CNS disorders

US6232316A · kind A · utility

Assignee

• Targacept, Inc. · US

Inventors

• Gary Maurice Dull · Lewisville, US
• William Scott Caldwell · Winston-Salem, US
• Patrick M. Lippiello · Clemmons, US
• Merouane Bencherif · Winston-Salem, US

Key dates

• Filing date: Jun 16, 1998
• Grant date: May 15, 2001
• Expiry date: Jun 16, 2018

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D239/26
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Pharmaceutical compositions incorporate aryl substituted olefinic amine compounds. Representative compounds are (4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-pyrimidinyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(6-amino-5-methyl-3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-bromo-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-ethoxy-3-pyridyl)-4-penten-2-amine, (2S)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine and (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine.